Splice time

How Skyhawk targets RNA splicing in cancer and exon-skipping diseases

Skyhawk Therapeutics Inc. is developing small molecules that manipulate the stability of the spliceosome during RNA processing to correct splicing defects that drive disease. Instead of focusing on genes in classic exon-skipping diseases, the newco is applying its strategy to otherwise “undruggable” targets in cancer, neurodegeneration and rare diseases.

CEO Kathleen McCarthy said Skyhawk’s compounds prevent RNA mis-splicing prior to protein translation, allowing the

Read the full 631 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE